backache; toe cramps; eye pain; numbness in face; headache; application site numbness; this is a spontaneous report received from a contactable reporter(s) (consumer or other non hcp) from a regulatory authority. regulatory number: gb-mhra-webcovid-202202240813490130-sqa7s. other case identifier(s): gb-mhra-adr 26645250. a 13 year-old male patient received bnt162b2 (comirnaty), administration date 20feb2022 (lot number: fl9994) at the age of 13 years as dose 2, single for covid-19 immunisation. relevant medical history included: "suspected covid-19", stop date: 23feb2022, notes: unsure when symptoms started. the patient's concomitant medications were not reported. vaccination history included: covid-19 vaccine (dose 1; manufacturer unknown), for covid-19 immunisation. the following information was reported: headache (medically significant) with onset 20feb2022, outcome "recovered" (24feb2022), described as "headache"; vaccination site hypoaesthesia (medically significant) with onset 20feb2022, outcome "recovered" (feb2022), described as "application site numbness"; eye pain (medically significant) with onset 21feb2022, outcome "recovering", described as "eye pain"; hypoaesthesia (medically significant) with onset 21feb2022, outcome "recovering", described as "numbness in face"; muscle spasms (medically significant) with onset 22feb2022, outcome "recovered" (23feb2022), described as "toe cramps"; back pain (medically significant) with onset 23feb2022, outcome "recovered" (feb2022), described as "backache". the patient underwent the following laboratory tests and procedures: sars-cov-2 test: no - negative covid-19 test. the patient had not been tested positive for covid-19 since having the vaccine. the patient was not enrolled in clinical trial. no follow-up attempts are needed. no further information is expected